Company news

Arcutis Biotherapeutics, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Arcutis Announces New Coverage for ZORYVE® (Roflumilast) Cream 0.3% with National and Regional Health Plan Formularies, Bringing Total Commercial Covered Lives to Over 110 Million

April 4, 2023

Arcutis Presents Late-Breaking Data from the INTEGUMENT Phase 3 Trials in Atopic Dermatitis at American Academy of Dermatology Annual Meeting

March 17, 2023

Arcutis to Present New Topical Roflumilast Data Including Late Breaking Atopic Dermatitis Pivotal Trial Data During the American Academy of Dermatology (AAD) Annual Meeting

March 8, 2023

Arcutis Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

February 27, 2023

Arcutis Submits Topical Roflumilast Foam 0.3% New Drug Application to the FDA for the Treatment of Seborrheic Dermatitis in Adults and Adolescents

February 20, 2023

Arcutis to Report Fourth Quarter 2022 Financial Results and Participate in Upcoming Investor Conference

February 7, 2023

Arcutis Presents New Phase 2 Long-Term Data Showing Sustained Efficacy and Clearance for a Median of 10 Months with Roflumilast Cream in Adults with Chronic Plaque Psoriasis

January 13, 2023

Arcutis Submits Supplemental New Drug Application for ZORYVE® (roflumilast) Cream 0.3% for Expanded Indication for the Treatment of Plaque Psoriasis in Children Down to 2 Years of Age

December 18, 2022

Arcutis Announces Positive Topline Results from Second Atopic Dermatitis Pivotal Phase 3 Trial of Roflumilast Cream in Adults and Children Aged 6 and Older

December 11, 2022

Arcutis Enrolls First Patient in Phase 1b Alopecia Areata Study Evaluating ARQ-255

December 4, 2022

Study Showing Significant Improvements in Itch and Itch-Related Sleep Loss with Roflumilast Cream in Adults with Plaque Psoriasis Published in American Journal of Clinical Dermatology

November 27, 2022

Arcutis Biotherapeutics Publishes First Environmental, Social, and Governance (ESG) Report

November 20, 2022

Arcutis’ ZORYVE® (Roflumilast) Cream 0.3% Added to Express Scripts, Inc.® National Formularies in the United States

November 16, 2022

Arcutis Announces Positive Topline Results from INTEGUMENT-1 Pivotal Phase 3 Trial of Roflumilast Cream in Atopic Dermatitis in Adults and Children Aged Six Years and Older

November 14, 2022

Arcutis Announces Third Quarter 2022 Financial Results and Provides Business Update

November 7, 2022

Arcutis to Report Third Quarter Financial Results

October 24, 2022

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

October 5, 2022

Arcutis Announces Positive Topline Results from ARRECTOR Pivotal Phase 3 Trial of Roflumilast Foam 0.3% in Scalp and Body Psoriasis

September 25, 2022

Journal of the American Medical Association Publishes Roflumilast Cream 0.3% Results from Pivotal DERMIS-1 and -2 Phase 3 Trials in Plaque Psoriasis

September 19, 2022

New Data from Arcutis’ STRATUM Pivotal Phase 3 Trial of Roflumilast Foam 0.3% in Seborrheic Dermatitis Presented at European Academy of Dermatology and Venereology (EADV) Congress

September 8, 2022

Arcutis Announces Acquisition of Ducentis BioTherapeutics Ltd.

September 6, 2022

New Data from Arcutis’ Topical Roflumilast Clinical Program Presented at the European Academy of Dermatology and Venereology (EADV) Congress

September 5, 2022

Arcutis Announces Appointment of Neha Krishnamohan to Board of Directors

September 1, 2022

New campaign from Arcutis aims to expose the impact of psoriasis on physical, mental, and emotional wellbeing

August 29, 2022

Arcutis Completes Enrollment in INTEGUMENT-2 Pivotal Phase 3 Trial of Roflumilast Cream in Atopic Dermatitis

August 22, 2022

Arcutis Announces Arcutis Cares™ Patient Assistance Program (PAP) For Financially Qualified Uninsured and Underinsured Patients

August 21, 2022

Arcutis Launches ZORYVE™ (Roflumilast) Cream 0.3% in the United States for Treatment of Plaque Psoriasis in Individuals Age 12 and Older

August 9, 2022

Arcutis Completes Enrollment in INTEGUMENT-1 Pivotal Phase 3 Trial of Roflumilast Cream in Atopic Dermatitis

August 3, 2022

Arcutis Announces Second Quarter 2022 Financial Results and Provides Business Update

August 3, 2022

Arcutis Biotherapeutics Announces Proposed Public Offering of Common Stock

August 1, 2022

Arcutis Biotherapeutics Announces Pricing of Public Offering of Common Stock

August 1, 2022

Arcutis to Host Investor Conference Call Today to Discuss the FDA Approval of ZORYVE™ (roflumilast) Cream 0.3% for Plaque Psoriasis

July 31, 2022

FDA Approves Arcutis’ ZORYVE™ (Roflumilast) Cream 0.3% For the Treatment of Plaque Psoriasis in Individuals Age 12 and Older

July 28, 2022

Arcutis Biotherapeutics Announces Health Canada Accepts for Review the New Drug Submission for Roflumilast Cream for Adults and Adolescents with Plaque Psoriasis

July 10, 2022

Arcutis Announces Positive Topline Results from STRATUM Pivotal Phase 3 Trial of Roflumilast Foam 0.3% in Seborrheic Dermatitis

June 5, 2022

CORRECTION: Nationwide Survey of People with Seborrheic Dermatitis Reveals Dissatisfaction with Current Treatment Options and Burden of Daily Care

May 24, 2022

Arcutis Announces First Quarter 2022 Financial Results and Provides Business Update

May 4, 2022

Arcutis Completes Enrollment in ARRECTOR Pivotal Phase 3 Trial of Topical Roflumilast Foam in Scalp and Body Psoriasis

April 5, 2022

Arcutis Presents New Data on Once-Daily Roflumilast Cream for Plaque Psoriasis from DERMIS Phase 3 Trials at American Academy of Dermatology Annual Meeting

March 24, 2022

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

March 13, 2022

Arcutis Announces Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update

February 21, 2022

Arcutis Completes Enrollment of STRATUM Pivotal Phase 3 Trial of Topical Roflumilast Foam in Individuals with Seborrheic Dermatitis

January 31, 2022

Arcutis Biotherapeutics Secures $225 Million in Non-Dilutive Debt Financing from SLR Capital Partners

December 22, 2021

FDA Accepts Arcutis Biotherapeutics’ New Drug Application for Roflumilast Cream for Adults and Adolescents with Plaque Psoriasis

December 21, 2021

Arcutis Appoints Mas Matsuda as General Counsel and Corporate Secretary

December 15, 2021

Arcutis Announces Data Comparing the Vehicle in Investigational Roflumilast Cream Against a Commercial Ceramide-Containing Moisturizing Cream

December 12, 2021

Arcutis Announces Third Quarter 2021 Financial Results and Provides Business Update

November 3, 2021

Arcutis Submits Topical Roflumilast Cream New Drug Application to FDA for the Treatment of Adults and Adolescents with Plaque Psoriasis

October 3, 2021

Arcutis Expands Patent Portfolio with Roflumilast Pharmacokinetics Patent

September 27, 2021

Arcutis Announces Appointment of Keith Leonard to Board of Directors

September 1, 2021

← Newer news releases · Older news releases →

Calls

The 5 newest of 16 calls. Every call is listed under its year.

Decks

The 5 newest of 27 decks. Every deck is listed under its year.